Supplementary Figure S3 from Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody
Year: 2026
Type: supplementary-materials
Abstract: Supplementary Figure S3. Kaplan–Meier analysis of DoR in patients who had an objective response to volrustomig IV Q3W in the dose-exploration and 2000 mg expansion cohorts.
Authors: Ben Tran, Mark Voskoboynik, Sang-We Kim, Charlotte Lemech, Enric Carcereny, Sun Young Rha, Myung-Ju Ahn, Enriqueta Felip, Ki Hyeong Lee, Eduardo Castañón Álvarez, James Chih-Hsin Yang, Paolo Antonio Ascierto, Mariano Provencio Pulla, Shunsuke Kondo, Yasutoshi Kuboki, Daniel Freeman, Xuyang Song, Jorge Blando, Steven Eck, Florian J. Song, Zoey Tang, Michael Kuziora, Shelby D. Gainer, Patrick Mitchell, Julie Asare, Amal Ayyoub, Ikbel Achour, Deepa S. Subramaniam, Seock-Ah Im
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7169598253